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Type 1 regulatory T (Tr1) cells play a pivotal role in restraining
human T-cell responses toward environmental allergens and pro-
tecting against allergic diseases. Still, the precise molecular cues that
underlie their transcriptional and functional specification remain
elusive. Here, we show that the cytokine activin-A instructs the
generation of CD4+ T cells that express the Tr1-cell–associated
molecules IL-10, inducible T-Cell costimulator (ICOS), lymphocyte
activation gene 3 protein (LAG-3), and CD49b, and exert strongly
suppressive functions toward allergic responses induced by naive
and in vivo-primed human T helper 2 cells. Moreover, mechanistic
studies reveal that activin-A signaling induces the activation of the
transcription factor interferon regulatory factor (IRF4), which, along
with the environmental sensor aryl hydrocarbon receptor, forms a
multipartite transcriptional complex that binds in IL-10 and ICOS
promoter elements and controls gene expression in human CD4+
T cells. In fact, IRF4 silencing abrogates activin-A–driven IL10 and
ICOS up-regulation and impairs the suppressive functions of human
activin-A–induced Tr1-like (act-A–iTr1) cells. Importantly, using a hu-
manized mouse model of allergic asthma, we demonstrate that
adoptive transfer of human act-A–iTr1 cells, both in preventive
and therapeutic protocols, confers significant protection against car-
dinal asthma manifestations, including pulmonary inflammation.
Overall, our findings uncover an activin-A–induced IRF4-aryl hydro-
carbon receptor (AhR)–dependent transcriptional network, which
generates suppressive human Tr1 cells that may be harnessed for
the control of allergic diseases.
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Overactive T helper 2 (Th2) cell-driven responses againstinhaled allergens contribute to the development of airway
inflammation and airway hyperresponsiveness (AHR), and are
associated with allergic asthma, a rising health care problem
worldwide (1). Regulatory T (Treg) cells and, specifically, IL-10–
producing type 1 Treg (Tr1) cells exert crucial nonredundant
functions in restraining exuberant Th2 responses and maintaining
tolerance in mouse models of experimental asthma (2–5). More-
over, in humans, the balance between allergen-specific Tr1 and
Th2 cells is considered decisive for the outcome of allergic re-
sponses (6). In fact, the tolerogenic effects of allergen-specific im-
munotherapies are associated with the generation of Tr1 cells (7).
Hence, the identification of factors that can induce and/or expand
human Tr1 cells represents an attractive therapeutic approach for
the control of allergic responses and linked asthmatic disease.
Despite recent advances in deciphering the human Tr1-cell
transcriptional network, the molecular cues that control the differ-
entiation of Tr1 cells remain largely unknown (8, 9). Seminal studies
have demonstrated that aryl hydrocarbon receptor (AhR), along
with the c-Maf proto-oncogene transcription factor (c-Maf), partic-
ipate in human Tr1-cell generation; still, these transcription factors
also contribute to the differentiation of other Th subsets, and thus
cannot be considered as Tr1-cell lineage specification factors (8–10).
Moreover, the precise molecular pathways underlying the suppres-
sive functions of human Tr1 cells remain incompletely defined.
Activin-A is a member of the TGF-β superfamily, initially de-
scribed as a gonadal protein stimulating the biosynthesis and se-
cretion of follicle-stimulating hormone (11). Since then, a growing
body of evidence has uncovered critical functions for activin-A as a
cytokine in fundamental biological processes, including develop-
ment, hematopoiesis, tissue repair, stem cell maintenance, and
differentiation (12). In line with this evidence, mice lacking the βA
subunit of activin-A die after birth due to severe craniofacial de-
fects, whereas mice lacking the βB subunit exhibit abnormal de-
velopment and reduced reproductive capacity (13, 14). Activin-A
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signals through a heterotetrameric receptor complex consisting of
two types of activin receptors: the type I activin-like kinase (ALK2,
ALK4, and ALK7) receptors and the type II activin (ActRIIA and
ActRIIB) receptors, which, upon activation, phosphorylate receptor-
regulated Smads (R-Smads) that translocate in the cell nucleus and
regulate gene transcription (15). Activin-A exerts both beneficial
and detrimental effects on allergic inflammation and linked diseases,
depending on the route of administration and the spatiotemporal
context (16, 17). Our previous studies, using an ovalbumin-induced
mouse model of allergic airway inflammation, have revealed that
activin-A protects against experimental asthma partly through the
generation of Foxp3−IL-10+ Treg cells (18). Moreover, we and
others have shown that activin-A and its signaling components are
induced in T cells infiltrating the lungs of asthmatics and become
further up-regulated following in vivo inhalational allergen challenge
(19, 20). Still, the effects of activin-A on the generation of human
Treg cells suppressive against allergic responses, and the molecular
mechanisms involved, remain unexplored.
Here, using an experimental approach that combines in vitro
priming of human naive T cells with ex vivo analysis of T-effector
cells, we demonstrate that activin-A instructs the differentiation
of human IL-10–producing Tr1-like cells that inhibit allergen-induced
T-cell responses. Mechanistic studies show that activin-A signaling
induces the activation of IRF4 in human T cells, which binds in IL10
and ICOS promoter elements and controls gene expression. More-
over, our findings reveal that IRF4, along with AhR and its binding
partner, AhR nuclear translocator (ARNT), form a transcription
factor complex that is essential for effector molecule expression by
human Tr1 cells. We further demonstrate that in vivo administration
of human activin-A–induced Tr1-like (act-A–iTr1) cells can prevent,
and even reverse, established allergic airway inflammation and confer
protection against asthma manifestations in an IL-10–dependent
manner. Collectively, our studies unravel activin-A as an inducer of
human Tr1 cells that may be exploited for the suppression of allergic
inflammation and the reestablishment of tolerance.
Results
Activin-A Drives the Differentiation of IL-10–Producing Human Tr1-Like
Cells. To delineate the effects of activin-A on the regulation of hu-
man T-cell–driven allergic responses, we used our well-established
in vitro T-cell priming model (21, 22). Briefly, we sorted naive
CD4+ T cells from the peripheral blood of atopic individuals and
stimulated them with allergen-loaded, mitomycin-treated, CD3-
depleted antigen-presenting cells (APCs) in the presence of
activin-A or control (PBS) (Fig. S1). This protocol has been shown
to skew T-cell responses toward Th2 (23). Indeed, control-treated
CD4+ T cells (hereafter referred to as Tconv cells) exhibited
marked proliferation, concomitant with high percentages of IL-4+
and IL-13+ cells and moderate to low IFN-γ+ (IFN-γ) and IL-17+
cells following allergen exposure, whereas T cells stimulated in the
absence of allergen did not exhibit discernible proliferation (Fig. 1
A and B and Fig. S2 A and B). In contrast, activin-A–stimulated
T cells displayed a reduced proliferative capacity and significantly
decreased percentages of cytokine-producing cells (Fig. 1 A and B
and Fig. S2B). Remarkably, activin-A significantly increased the
frequencies of CD4+IL-10+ T cells (Fig. 1A and Fig. S2B). In
accordance with the flow cytometry data, activin-A–treated human
T cells expressed low levels of mRNAs encoding IL-4, IL-13, IL-5,
IFN-γ, and IL-17, whereas IL-10 levels were increased (Fig. S2C).
Moreover, IL-4, IL-13, and IFN-γ release in culture supernatants
was decreased, whereas IL-10 production was significantly elevated
in the presence of activin-A (Fig. 1C). Blockade of TGF-β in pri-
mary induction cultures did not affect the activin-A–mediated in-
crease in the percentages of CD4+IL-10+ T cells (Fig. S2D).
Interestingly, activin-A–treated T cells remained unresponsive
upon secondary restimulation with fresh allergen-loaded APCs
(Fig. S3 A and B). This hyporesponsiveness was not associated
with induction of T-cell apoptosis/necrosis, as reflected by similar
frequencies of 7AAD+Annexin-V+CD4+ T cells among activin-A–
and control-treated T cells (Fig. S3C). In fact, addition of IL-2
reversed activin-A antiproliferative effects, similar to recent ob-
servations on human follicular helper T (Tfh) cells (24) (Fig. S3D).
Notably, activin-A–treated CD4+ T cells exhibited Ag specificity
because allergen-primed T cells retained their ability to respond
upon subsequent exposure to tetanus toxoid, an irrelevant antigen
(Fig. S3E). Activin-A significantly decreased T-cell proliferation
and enhanced the frequencies of CD4+IL-10+ T cells in the con-
text of anti-CD3/CD28 stimulation in the absence of APCs,
pointing to direct effects on CD4+ T cells that are not associated
with regulation of APC functions (Fig. S4 A and B).
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Fig. 1. Activin-A drives the differentiation of
human Tr1-like cells. (A) Human naive CD4+ T cells
were sorted from the peripheral blood of atopics;
labeled with CFSE; and stimulated with allergen
(mixed grasses extract)-loaded, mitomycin-treated,
CD3-depleted APCs in the presence of PBS (con-
trol) or activin-A for 7 d (or 9 d for IL-10) and
analyzed by flow cytometry. The percentages of
cytokine-producing T cells are shown. Data are
expressed as mean ± SEM and are pooled from
n = 8 independent experiments (n = 8 donors).
(B, Left) Representative FACS plots showing T-cell
proliferation gated on CD4+ T cells. Max, maxi-
mum. (B, Right) Cumulative data pooled from n =
6–8 independent experiments (n = 8 donors).
(C ) Cytokines in culture supernatants are shown.
Data are expressed as mean ± SEM of triplicate
wells and are pooled from n = 8 independent
experiments (n = 8 donors). (D) Representative
FACS plots showing ICOS and IL-10 expression
gated on CD4+ T cells. Cumulative data are pooled
from n = 6–8 independent experiments (n =
8 donors). (E ) Real-time PCR analysis of ICOS,
LAG3, GZMB, and IL10 mRNA levels in CD4+ T cells
stimulated as above for 3 d. Results are presented
relative to GAPDH and are pooled from n =
5 separate experiments (n = 5 donors). (F ) Rep-
resentative FACS plots (Left) and percentages
(Right) of LAG3+CD49b+ cells among CD4+IL-10+ICOS+ T cells are depicted. Data are pooled from n = 4–6 separate experiments (n = 6 donors).
Statistical significance was obtained by the Student’s t test (*P < 0.05; **P < 0.01; ***P < 0.001).
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To characterize the immunophenotype of activin-A–treated
human T cells further, we investigated the expression of Treg-cell–
associated markers. PD-1, GITR, and CTLA-4 were expressed at
equivalent levels between activin-A– and control-treated T cells
(Fig. S5 A and B). Moreover, Foxp3 expression did not differ
between the two groups (Fig. S5 C and D). Still, ICOS levels were
markedly increased upon stimulation with activin-A, whereas the
T-cell activation markers CD69, CD25, and CD127 were de-
creased (Fig. S5 A and B). CRTh2, CCR3, CCR4, CCR5, CCR6,
and CXCR3 were dampened in activin-A–treated T cells, whereas
CCR7 was increased (Fig. S6 A and B). Interestingly, we observed
a striking increase in the percentages of ICOS+IL-10+CD4+
T cells among activin-A–treated T cells, accompanied by markedly
elevated IL10 and ICOS mRNA levels (Fig. 1 D and E). More-
over, a large proportion of CD4+ICOS+IL-10+ T cells among
activin-A–treated T cells expressed CD49b and LAG3, recently
identified as human Tr1-cell–associated markers (25), concomi-
tant with a significant increase in the mRNAs encoding LAG3 and
GZMB (Fig. 1 E and F).
IL-10–induced human Tr1 cells, generated as previously de-
scribed (25), contained similar percentages of CD4+IL-10+ T cells,
compared with activin-A–treated CD4+ T cells, whereas LAG-3
and CD49b expression was increased in IL-10–induced Tr1 cells
(Fig. S7 A and B). The expansion of activin-A–treated CD4+
T cells in culture was significantly increased compared with the
expansion of IL-10–induced Tr1 cells, which exhibited poor ex-
pansion in agreement with previous studies (25) (Fig. S7C).
Notably, even after prolonged (4 wk) T-cell receptor stimulation,
CD4+ T cells stimulated with activin-A did not express Th-effector
cytokines, although they maintained high frequencies of CD4+IL-
10+ICOS+ T cells (Fig. S8 A–C). Collectively, these findings reveal
that activin-A stimulation restrains allergen-driven human T-cell
responses and instructs the differentiation of IL-10–producing Tr1-
like cells.
Activin-A–Induced Human Tr1-Like Cells Display Strong Suppressive
Functions. On the basis of the aforementioned findings, we next
explored whether stimulation with activin-A endows human
T cells with immunoregulatory functions. To address this issue,
we cocultured carboxyfluorescein succinimidyl ester (CFSE)-
labeled, activin-A–treated, or control-treated T cells, as poten-
tial suppressors, with autologous Cell Trace Violet-labeled naive
CD4+ T responders and allergen-primed APCs. Our data showed
that activin-A–treated T cells greatly suppressed the proliferation
of T responders, even at high T-responder/T-suppressor ratios
(Fig. 2 A and B). Moreover, act-A–iTr1 cells significantly de-
creased IL-5 and IL-13 release in culture supernatants (Fig. 2C).
Still, IFN-γ levels remained unaltered, possibly due to activation of
a counterbalancing mechanism used by act-A–iTr1 cells to inhibit
Th2 cytokine secretion (Fig. S9A). In contrast, control-treated
T cells did not exhibit discernible suppressor functions (Fig. 2
A–C). The proliferation of act-A–iTr1 cells remained low in sup-
pressive cultures (Fig. 2B). Naive T responders cultured with
allergen-pulsed APCs alone displayed enhanced proliferative
capacity, compared with the other groups (Fig. 2B). IL-10–induced
human Tr1 cells demonstrated an enhanced suppressive capacity
toward T-responder cell proliferation, compared with act-A–iTr1
cells (Fig. S7D).
To elucidate the mechanisms involved in the suppressive
functions of human act-A–iTr1 cells, we initially used a transwell
system. The suppressive capacity of activin-A–treated CD4+
T cells across a permeable membrane was decreased, but not
abolished, in this setting, pointing to the involvement of both cell
contact-dependent and independent mechanisms (Fig. 2D). Indeed,
transfer of the conditioned medium (CM) obtained from the
supernatants of act-A–iTr1 cells to fresh CD4+ T-cell/APC cocul-
tures suppressed T-responder proliferation (Fig. 2E). Interestingly,
IL-10 production was significantly increased in secondary cultures
(Fig. 2E). Disruption of IL-10 signaling, using an antibody against
the IL-10 receptor (IL-10R) in secondary cultures, partially
reversed the inhibitory effects of the CM obtained from act-A–
iTr1 cells, emphasizing the involvement of IL-10 in their sup-
pressive functions (Fig. 2F). Blockade of IL-10, TGF-β, or ICOS
signaling in secondary suppressive cultures partly impaired the
suppressive capacity of act-A–iTr1 cells, whereas blockade of
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Fig. 2. Activin-A–induced human Tr1-like cells display strong suppressive func-
tions. (A) Human naive CD4+ T cells were stimulated with allergen-loaded,
mitomycin-treated APCs in the presence of PBS (Tconv) or activin-A (act-A-iTr1)
cells, and T cells were then isolated and cocultured with autologous naive CD4+ T
responders (at the indicated ratios) in the presence of allergen-loaded APCs for
4 d. 3[H]Thymidine incorporation is shown. Data are representative of n = 3 in-
dependent experiments (n = 3 donors). TdR, tritiated thymidine. (B) Tconv or act-
A–iTr1 cells were generated as in A, CFSE-labeled, and cocultured with Cell Trace
Violet-labeled autologous naive CD4+ T responders and allergen-loaded,
mitomycin-treated APCs. Representative FACS plots showing T-cell proliferation
(Left) and cumulative data (Right), shown as mean ± SEM, are pooled from n =
6–8 separate experiments (n = 8 donors). (C) Th2 cytokines in culture super-
natants are shown. Data are expressed as mean ± SEM of triplicate wells and are
pooled from n = 6–8 separate experiments (n = 8 donors). (D) Tconv or act-A–
iTr1 cells and allergen-loaded APCs were cultured in a transwell system across
from cocultures of autologous naive CD4+ T cells and APCs. Suppression of
T-responder proliferation is shown. Data are expressed as mean ± SEM of trip-
licate wells and are pooled from n = 3 independent experiments (n = 3 donors).
(E) CM from Tconv or act-A–iTr1 culture supernatants was added to naive CD4+
T-cell/APC cocultures. 3[H]Thymidine incorporation and IL-10 release are depic-
ted. Data are expressed as mean ± SEM of triplicate wells and are pooled from
n = 4–6 separate experiments (n = 4 donors). (F) CM from Tconv or act-A–
iTr1 culture supernatants was added to naive CD4+ T-cell/APC cocultures,
as indicated. 3[H]Thymidine incorporation is depicted, and data are expressed
as mean ± SEM of triplicate wells and pooled from n = 3–4 experiments (n =
4 donors). Statistical analysis was performed by the Student’s t test (A–C and
E) and a nonparametric (Mann–Whitney) unpaired Student’s t test (D and F)
(*P < 0.05; **P < 0.01; ***P < 0.001).
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activin-A did not significantly affect their functions (Fig. S9B).
Concomitant blocking of IL-10, TGF-β, and ICOS signaling further
reduced act-A–iTr1 cell inhibitory functions, compared with
blocking each pathway alone or combinations of two; however, the
data did not reach statistical significance (Fig. S9B). Overall, these
findings reveal that human act-A–iTr1 cells exhibit robust sup-
pressive functions against naive and effector T-cell responses to
allergen through IL-10–, TGF-β–, and ICOS-dependent pathways.
IRF4 Is Activated in Human Act-A–iTr1 Cells and Forms Multipartite
Complexes with AhR in the ICOS Promoter. We next attempted to
decipher the transcriptional pathways contributing to activin-A–in-
duced human Tr1-cell differentiation. Investigation of the expression
of the major Th-cell lineage–associated transcription factors TBX21,
GATA3, and RORC at an earlier time point (day 3) during T-cell
differentiation demonstrated that mRNA levels were similar or
slightly decreased in act-A–iTr1 cells, whereas FOXP3 was moder-
ately increased, compared with Tconv cells (Fig. 3A). Interestingly,
act-A–iTr1 cells expressed increased transcripts of the Tr1-cell–
associated transcription factors MAF (encoding c-Maf) and AHR,
along with its major gene target, xenobiotic metabolizing enzyme
cytochrome P450, encoded by CYP1A1 (8) (Fig. 3A). Moreover,
activin-A stimulation induced a marked up-regulation in the mRNA
levels of IRF4, a transcription factor not previously associated with
human or mouse Tr1 cells (Fig. 3A). Inhibition of activin-A signal-
ing, using an anti-ALK4 antibody or the Smad3 inhibitor (SIS3),
decreased activin-A–induced gene transcription, pointing to the
involvement of its canonical signaling pathways (Fig. 3B). Con-
focal microscopy studies demonstrated that activin-A stimulation
induced an enhanced translocation of IRF4, c-Maf, and AhR into
the nucleus of human CD4+ T cells (Fig. 3C).
Comparison of the global gene expression profile of human act-
A–iTr1 cells with the global gene expression profile of Tconv cells,
using RNA-sequencing (RNA-seq) analysis, revealed notable dif-
ferences in their transcriptome profile, with 513 genes being sig-
nificantly differentially regulated, 200 of which were down-regulated
and 313 of which were up-regulated (Fig. S10 A and B). Volcano
plot visualization demonstrated that the transcriptional signature
of act-A–iTr1 cells was characterized by substantial changes
compared with Tconv cells, with nearly 50% of the total differ-
entially expressed genes showing a difference in expression greater
than twofold [log2 (fold change [FC]) < −1 or > 1] (Fig. S10A).
These genes belonged to biologically important gene families,
including chemokines/cytokines or their receptors, transcription
factors, surface receptors, and Treg-cell markers (Fig. S10B). In-
terestingly, several genes, including LAG3, IRF4, GZMB, CCL1,
CSF2, DGKI, CD70, and EBI3, were enriched in both human act-
A–iTr1 cells and IL-10–induced Tr1 cells (25), whereas others,
such as CCL18, WNT2B, MMP15, and CD163, were down-
regulated in both groups (Fig. S10C).
In view of the aforementioned findings, we hypothesized that
activin-A up-regulates IL10 and ICOS expression in human
CD4+ T cells through IRF4-, AhR-, and c-Maf–dependent
pathways. To examine this hypothesis, we initially performed bio-
informatics analysis to decipher whether these transcription factors
have putative binding sites in human IL10 and ICOS gene loci.
Indeed, we identified two IRF4-binding sites [IFN-stimulated re-
sponse elements (ISREs)] in the IL10 promoter and three ISREs in
the ICOS locus (Fig. 4 A and B). In agreement with previous
studies, we found a putative AhR-binding site [xenobiotic response
element (XRE-1)] and a c-Maf site [MAF-recognition element
(MARE-1)] within the IL10 promoter, which were in high proximity
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Fig. 3. IRF4, AhR, and c-Maf are activated upon stimulation of human CD4+
T cells with activin-A. (A) Human naive CD4+ T cells were stimulated with
allergen-loaded, mitomycin-treated APCs in the presence of PBS or activin-A
for 3 d. Real-time PCR analysis of the indicated genes is shown. Results are
representative of n = 4 separate experiments (n = 4 donors) and were nor-
malized to GAPDH. (B) Tconv or act-A–iTr1 cells were generated as above
with an anti-ALK4 blocking antibody or the Smad3 inhibitor, SIS3. Real-time
PCR results are shown relative to GAPDH. Data are representative of n = 4
independent experiments (n = 4 donors). (C–E) Confocal microscopy images
of Tconv or act-A–iTr1 cells stained with fluorescently conjugated anti-AhR,
anti-IRF4, and anti–c-Maf antibodies. Nuclei are stained blue with DAPI.
(Scale bars: IRF4 images, 4 μm; AhR and c-Maf images, 2 μm). Cumulative
data showing the percentages of AhR+, IRF4+, or c-Maf+ T cells were pooled
from n = 4 independent experiments (n = 4 donors). Statistical analysis was
performed by a nonparametric (Mann–Whitney) unpaired Student’s t test
(*P < 0.05; **P < 0.01).
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and partially overlapping (8) (Fig. 4A). Moreover, we identified a
c-Maf–binding site (MARE-2, −150 bp) in the IL10 promoter and
two XRE and five MARE sites in the ICOS locus (Fig. 4 A and B).
We next focused on investigating whether activin-A signaling
in CD4+ T cells induces the binding of IRF4, AhR, and c-Maf to
their response elements in IL10 and ICOS loci. Chromatin im-
munoprecipitation (ChIP) assays revealed a marked enrichment
of IRF4 binding to the ISRE (−318 bp) site in the IL10 promoter
in act-A–iTr1 cells, compared with Tconv cells (Fig. 4C). In
addition, AhR and c-Maf bound on the XRE-1 (−230 bp) and
MARE-1 (−200 bp) sites, respectively, in the IL10 promoter in
human act-A–iTr1 cells (Fig. 4C). In contrast, AhR showed no
discernible binding to the XRE-1 element in the IL10 promoter
in Tconv cells, whereas c-Maf bound moderately to its MARE-1
site (Fig. 4C). Pertinent to the ICOS locus, our data showed that
IRF4 exhibited great enrichment to its ISRE (−1.3 kb) site,
whereas AhR bound to its respective XRE site (−1,440 bp) in act-
A–iTr1 cells (Fig. 4D). Modest binding of c-Maf to the MARE site
(−1,330 bp) in the ICOS locus was also observed (Fig. 4D).
The ability of IRF4 and AhR to bind to the ICOS promoter in
human T cells in response to activin-A stimulation, and the
proximity of their binding sites, prompted us to explore whether
they form transcriptional complexes at the ICOS locus. To address
this issue, we performed sequential ChIP analysis of activin-A– or
Tconv cells. Remarkably, our findings identified the presence of
IRF4/AhR complexes in the ICOS promoter in act-A–iTr1 cells,
but not in Tconv cells (Fig. 4E).
To dissect the molecular interactions of IRF4 with AhR fur-
ther, we performed in silico analysis of putative protein–protein
interactions between the two transcription factors. Because a
description of the solved structures of the full-length sequences
of these transcription factors is currently lacking, reliable models
were constructed and submitted for molecular docking. Interest-
ingly, our studies revealed that IRF4 and AhR can form a tri-
partite molecular complex together with the AhR-binding partner,
ARNT (26) (Fig. 4F). This complex was highly stable thermody-
namically because after the minimization of its energy, it was
characterized by an energy value of −260685.0 KJ/mol. Moreover,
this structure remained stable throughout the duration (10 ns) of
the molecular dynamics simulation studies. Additionally, when this
energetically minimized complex was superimposed with the initial
docking output, the rmsd values between the carbon α-atoms were
extremely low (Cα rmsd values at 0.52 Å). Together, this evidence
supports the notion that the proposed docking result of IRF4/AhR
is highly reliable and exhibits high thermodynamic stability.
These results collectively demonstrate that activin-A induces the
activation of IRF4, AhR, and c-Maf in human CD4+ T cells, which
bind in their response elements in IL-10 and ICOS promoters
through the formation of multipartite transcriptional complexes.
IRF4 and AhR Signaling Is Essential for Activin-A–Induced Human Tr1-
Cell Differentiation. To obtain functional evidence that IRF4 is
involved in activin-A–mediated differentiation of human Tr1-like
cells, we used IRF4-specific shRNA (shIRF4) to target IRF4 ex-
pression in T cells directly. Briefly, CD4+ T cells transduced with
lentiviral particles containing constructs of GFP-shRNA for IRF4
were sorted based on viability and GFP expression, and used in in
vitro suppression assays. Indeed, knockdown of IRF4 decreased
IRF4, ICOS, and IL10 mRNA levels in CD4+ T cells in response
to activin-A (Fig. 5A). The percentages of LAG-3+CD49b+ T cells
were also decreased, compared with sh-scrambled–treated, activin-
A–stimulated T cells (Fig. S10D). IRF4 silencing also compromised
the suppressive functions of act-A–iTr1 cells and partly reversed
their hypoproliferative state (Fig. 5B and Fig. S10E).
Because IRF4 assembles into a complex with AhR in human
T cells in response to activin-A, we next explored the role of
AhR in activin-A–induced responses using CH-223191, a potent
AhR antagonist (8). Pharmacological blockade of AhR nearly
abrogated activin-A–induced AhR activation, as shown by a
marked down-regulation of CYP1A1 mRNA (Fig. 5C). Interest-
ingly, inhibition of AhR signaling partly reversed activin-A–induced
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Fig. 4. IRF4 assembles into a complex with AhR in the ICOS promoter in
human act-A–iTr1 cells. Schematic representation of the human IL10 pro-
moter (A) and ICOS locus (B); the c-Maf, AhR, and IRF4 putative binding sites
are shown. Positions are given in base pairs relative to the transcription start
site. (C and D) Tconv or act-A–iTr1 cells were generated following stimula-
tion with anti-CD3/CD28 antibodies in the presence of PBS or activin-A, re-
spectively. ChIP analysis of IRF4, AhR, and c-Maf binding in the IL10 (C) and
ICOS (D) promoters is shown. Data are presented as ± SEM and are pooled
from two independent experiments (n = 4 donors, two donors per experi-
ment). (E) Tconv or act-A–iTr1 cells were generated as in C. Sequential ChIP
analysis demonstrates IRF4 and AhR cobinding in the ICOS promoter. Data
are presented as mean ± SEM and are pooled from two independent ex-
periments (n = 4 donors, two per experiment). (F) Computational model of
the putative protein–protein interactions of IRF4 and AHR is shown in white
superimposed with the solved structures used for the homology modeling
(PDB ID codes 3DSH and 4ZPR). The template chain of the IRF4 model is
shown in orange. In the 4ZPR structure, the ARNT chain is shown in blue, the
AHR template chain is shown in light blue, and the DNA is shown in ma-
genta. Statistical analysis was performed by a nonparametric (Mann–Whitney)
unpaired Student’s t test (*P < 0.05).
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IL10, ICOS, andMAF up-regulation and significantly decreased the
frequencies of CD4+ICOS+IL-10+ T cells (Fig. 5C). In addition,
disruption of AhR signaling impaired the suppressive capacities of
act-A–iTr1 cells, accompanied by a significant reduction in IL-10
release (Fig. 5D). In summary, these results provide compelling
evidence that IRF4 and AhR are critically involved in activin-A–
induced differentiation of human Tr1-like cells.
In Vivo Administration of Human Act-A–iTr1 Cells Prevents the
Development of Allergic Airway Disease. Considering ongoing ef-
forts to use adoptive Treg-cell transfers as a therapy for immune-
mediated human diseases, the issue of their in vivo stability is of
critical clinical importance. To explore whether act-A–iTr1 cells
can maintain their suppressive functions upon transfer in vivo,
we used a well-established humanized mouse model of allergic
airway inflammation (23, 27, 28). Briefly, we transferred allergen-
primed human act-A–iTr1 or Tconv cells, along with autologous
APCs, into immunodeficient NOD-SCID mice and examined their
responses upon immunization and aerosol challenge with allergen
(Fig. S11A). Indeed, human CD4+ T cells isolated from the lymph
nodes (LNs) of NOD-SCID mice reconstituted with act-A–iTr1 cells
were able to suppress the proliferation and Th2 cytokine release
by cocultured naive T responders in ex vivo suppression assays
(Fig. S11B). In contrast, CD4+ T cells obtained from the LNs of
Tconv-cell–reconstituted mice did not exhibit discernible suppressor
functions (Fig. S11B). These data indicate that act-A–iTr1 cells can
retain their potent inhibitory functions against other T-cell responses
even following in vivo transfer into a highly inflammatory milieu.
Subsequently, we investigated whether in vivo administration of
human act-A–iTr1 cells in a preventive protocol could confer
protection against features of experimental asthma (Fig. S11C).
Indeed, adoptive transfer of act-A–iTr1 cells significantly de-
creased AHR to metacholine, a cardinal asthma manifestation,
induced by cotransferred human T effectors (Fig. 6A). Impor-
tantly, administration of act-A–iTr1 cells significantly dampened
inflammatory cell influx in the bronchoalveolar lavage (BAL) and
prevented the development of pulmonary inflammation (Fig. 6 B
and C). Tconv cells did not suppress airway inflammation or
AHR; in fact, allergic responses were enhanced compared with
recipients of T responders alone (Fig. 6 A–C). Considering the key
role of IL-10 in the suppressive functions of human act-A–
iTr1 cells in vitro, we examined its effects in vivo through ad-
ministration of an anti–IL-10R antibody (or an isotype-matched
control) (Fig. S11C). Disruption of IL-10 signaling partly reversed
the suppressive effects of act-A–iTr1 cells on AHR and lung in-
flammation, but did not affect inflammatory cell responses in the
BAL, compared with mice that received act-A–iTr1 cells but were
treated with the isotype-matched control antibody (Fig. 6 A–C).
To explore the effects of act-A–iTr1 cells on the regulation of
human T-effector responses in vivo, we isolated lung-draining
lymph node (DLN) cells and restimulated them with allergen
ex vivo. In line with the attenuated allergic airway disease se-
verity, the capacity of DLN cells to proliferate and secrete IL-13
was significantly decreased in mice cotransferred with act-A–
iTr1 cells, an effect that was partly reversed upon inhibition of
IL-10 signaling (Fig. 6D). Moreover, the frequencies of IL-4+
and IL-13+ CD4+ T-effector cells in the DLNs of mice admin-
istered act-A–iTr1 cells were significantly decreased, and this
effect was also reversed upon IL-10R blockade (Fig. 6E).
Altogether, these findings reveal that human act-A–iTr1 cells
retain their immunosuppressive properties upon transfer in vivo
and confer significant protection against asthma manifestations,
partly through an IL-10–dependent mechanism.
Therapeutic Administration of Human Act-A–iTr1 Cells Reverses
Established Allergic Responses and Ameliorates Asthma Severity.
To explore whether human act-A–iTr1 cells could reverse
ongoing allergic airway inflammation, we adoptively transferred
act-A–iTr1 cells, right before aerosol challenge, in mice recon-
stituted with T cells and sensitized to allergen (Fig. S11D). In-
deed, administration of act-A–iTr1 cells induced a significant
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Fig. 5. IRF4 and AhR drive activin-A–induced human Tr1 cell differentiation.
(A) Tconv or act-A–iTr1 cells were stimulated with APCs and allergen, and trans-
duced with shRNA against human IRF4 (sh-IRF4) or a scrambled nontargeting
control RNA sequence (sh-scr). Real-time PCR analysis is shown. Data are relative
to GAPDH and represent n = 3 independent experiments (n = 3 donors).
(B) Transduced act-A–iTr1 cells were cocultured with naive Cell Trace Violet-
labeled CD4+ T cells and allergen-loaded APCs. Representative FACS plots of
T-responder cell proliferation are shown. Cumulative data, shown as mean ± SEM,
depict suppression of proliferation (%) and are pooled from n = 4 separate ex-
periments (n = 4 donors). (C) Tconv or act-A–iTr1 cells were generated following
stimulation with allergen-loaded APCs in the presence or absence of the AhR
antagonist CH223191. (Left) Real-time PCR analysis is shown. Results are relative to
GAPDH and represent n = 4 separate experiments (n = 4 donors). (Right) Cu-
mulative data showing the percentages of CD4+ICOS+IL-10+ T cells summarize
four independent experiments (n = 4 donors). (D) Tconv or act-A–iTr1 cells, gen-
erated as in C, were isolated and cocultured with CD4+ T cells and allergen-loaded
APCs. 3[H]Thymidine incorporation and IL-10 release are shown. Data are mean±
SEM of triplicate wells and are pooled from n = 4 independent experiments (n =
2 donors). Statistical significance was obtained by the Student’s t test (*P < 0.05;
**P < 0.01; ***P < 0.001).
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decrease in AHR induced by human Th2-effector cells and at-
tenuated inflammatory cell infiltration in the lungs (Fig. 7 A and
B), suggesting that this regime may have applications in ame-
liorating disease manifestations.
Finally, to investigate whether our findings had potential clinical
relevance, we examined the effects of activin-A on the suppression of
T-cell responses to mixed grasses extract, a clinically relevant aller-
gen, from individuals with atopy as well as distinct asthma severities.
Interestingly, activin-A induced a significant decrease in robust pro-
liferative responses of CD4+ T cells to allergen in atopic individuals
and in subjects with mild/moderate and severe asthma (Fig. 7 C and
D and Fig. S12 A and B). This decrease was accompanied by a
substantial down-regulation in the release of IL-5 and IL-13 (Fig. 7 C
and D and Fig. S12 A and B). Notably, activin-A also restrained
T-cell responses, including IL-17 production, in a small group of
patients with severe, steroid-refractory asthma (Fig. S12 C and D).
Discussion
In the present studies, we uncover activin-A as an inducer of
human Tr1-like cells that exhibit highly suppressive functions
against allergen-induced naive and effector Th2 responses.
Moreover, our data underscore a crucial role for IRF4 in human
Tr1 cell biology, showing that in response to activin-A, IRF4 as-
sembles into a multipartite molecular complex with AhR and
controls Tr1-cell differentiation and effector functions. Of trans-
lational importance, we demonstrate that upon therapeutic trans-
fer in a humanized model of allergic asthma, act-A–iTr1 cells
confer protection against cardinal disease manifestations. Overall,
our studies highlight human act-A–iTr1 cells as potent therapeutic
targets that can be used for the design of novel cell-based im-
munotherapies aiming to control allergic diseases.
Using our established in vitro human T-cell priming model that
closely resembles the allergen sensitization phase, we demonstrated
that activin-A significantly inhibits T-cell proliferation and Th2-
effector cytokine release and renders human T cells hyporesponsive
following reexposure to allergen in vitro and adoptive transfer into
humanized mice in vivo. In addition, stimulation with activin-A
endowed human naive T cells with key Tr1-cell–associated char-
acteristics, such as expression of ICOS, LAG3, CD49b, and
granzyme-B as well as production of copious amounts of IL-10 (25,
29–31). Moreover, act-A–iTr1 cells exhibited potent suppressive
functions accompanied by enhanced expansion in culture, com-
pared with IL-10–induced Tr1 cells. Interestingly, RNA-seq analysis
of the global gene expression profile of human act-A–iTr1 cells,
compared with the recently identified LAG3+CD49b+ Tr1 cells,
uncovered several similarities in their transcriptional signatures.
Seminal studies have documented a critical role for activin-A in
instructing the differentiation of Tfh cells in humans and of Th9 and
induced Foxp3+ Treg cells in mice (17, 24, 32). Considering that
several cytokines induce the differentiation of Th cells into distinct
subsets depending on the context and the presence of other cyto-
kines in the micromilieu (33), our findings demonstrating that
activin-A can drive the differentiation of human Tr1-like cells ex-
tend the findings of previous reports.
An important finding of the present studies is the newly
identified role of IRF4 as an essential component of the tran-
scriptional network through which activin-A instructs human
Tr1-cell differentiation. IRF4 contributes to the generation of
several Th subsets, such as Th1, Th2, Th17, and T follicular
helper cells; still, its involvement in human Tr1 cell biology has
not been previously described (34, 35). Our findings demonstrate
that IRF4 knockdown impairs activin-A–induced IL10 and ICOS
up-regulation, decreases the percentages of LAG3+CD49b+
T cells, and compromises the suppressive functions of human
act-A–iTr1 cells. Moreover, using sequential ChIP experiments
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Fig. 6. In vivo administration of human act-A–iTr1 cells prevents allergic
airway disease. (A) AHR is depicted. Enhanced pause (PenH) results are
expressed as mean ± SEM. Data were analyzed by two-way ANOVA for re-
peated measures, followed by the Student’s t test, and are pooled from two
to three independent experiments (n = 4–6 mice per group). (B) Total BAL
cell numbers are shown. (C) Representative photomicrographs and histo-
logical scores of H&E-stained lung sections. (Scale bars: 50 μm). (D) DLN cells
were harvested at the time of euthanasia and restimulated with P. pratense.
3[H]Thymidine incorporation and IL-13 release in culture supernatants are
presented. Data are mean ± SEM of triplicate wells. (E) Percentages of
cytokine-producing human CD4+ T cells in the DLNs are shown. Data are
representative of two to three independent experiments (n = 4–6 mice per
group). Statistical analysis was performed by the Student’s t test (*P < 0.05;
**P < 0.01; ***P < 0.001).
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and computational studies, we provide evidence that IRF4 forms
a transcriptional complex with AhR and ARNT that seems to be
important for activin-A–induced ICOS up-regulation in Tr1 cells.
Considering that AhR and ARNT activate target gene expres-
sion through direct interactions with other transcription factors
(26), our data illuminate IRF4 as a key partner in AhR/ARNT-
driven ICOS regulation. Interestingly, ablation of a conditional
IRF4 allele in mouse Foxp3+ Treg cells reduces ICOS, Gzmb, and
IL-10 expression and decreases their inhibitory capacity upon
adoptive transfer in vivo, also implicating IRF4 in ICOS regulation
and Treg-cell functions (36). Taken together, it becomes evident
that IRF4 represents a central nodule of the transcriptional ma-
chinery that instructs effector molecule expression and suppressive
functions in both Foxp3+ Treg and Foxp3− Tr1 cells.
Our results also showed that inhibition of AhR signaling abro-
gates activin-A–induced IL10 and ICOS up-regulation and impairs
the inhibitory capacities of human act-A–iTr1 cells. Seminal studies
have demonstrated that, depending on the stimuli, signaling
through AhR drives the differentiation of human naive T cells into
either Foxp3+ Treg cells or Foxp3− Tr1 cells (8, 9). Our studies
strengthen this notion, adding activin-A to the team of factors that
use AhR-induced signals for the differentiation of human Tr1 cells.
Moreover, because in the presence of TGF-β, AhR activation leads
to the generation of Foxp3+ Treg cells, our findings reinforce the
concept that although belonging to the same superfamily, activin-A
and TGF-β exert disparate nonredundant functions on human
T-cell responses, instructing the differentiation of distinct Treg-cell
subsets (18). In agreement, neutralization of TGF-β did not affect
an activin-A–mediated increase in the percentages of CD4+IL-10+
T cells. In addition, given that AhR interacts with c-Maf to control
IL-27–driven IL-10 expression in mouse CD4+ T cells, interactions
between these transcription factors may also operate in our settings
and will be investigated in future studies (9).
A striking finding of our studies was that in vivo administration
of act-A–iTr1 cells prevented the development of allergen-driven
airway inflammation and ameliorated disease severity in a hu-
manized model of allergic asthma. Of high relevance to clinical
settings, we also showed that mice receiving act-A–iTr1 cells during
allergen inhalational challenge and after the establishment of al-
lergic inflammation exhibited dampened Th2-effector responses
and attenuated pulmonary inflammation, suggesting that this re-
gime may have therapeutic applications. Notably, the inhibitory
functions of act-A–iTr1 cells largely depended on IL-10 signaling
in vivo, further emphasizing the crucial role of IL-10 in the es-
tablishment of tolerance in the airway (4, 37). In severe asthma,
T-effector cells are overactivated and often become resistant to
mainstay immunosuppressive therapies, including corticoste-
roids. Given that activin-A was able to restrain allergen-driven
responses by T-effector cells from asthmatic individuals across
the spectrum of disease severity, our studies may mark this cy-
tokine as a potentially attractive therapeutic target for asthma.
In conclusion, we have identified an activin-A–induced, IRF4/
AhR-dependent transcriptional network that instructs the dif-
ferentiation of human Tr1 cells suppressive against Th2-cell–
mediated allergic responses. Considering that adoptive T-cell
therapies are underway to control immune-mediated diseases,
our findings illuminate act-A–iTr1 cells as targets that can be
exploited for the control of asthma and other human diseases
associated with dysregulated immunity.
Materials and Methods
Study Population. Peripheral blood samples were obtained from 13 atopic
individuals without asthma and 22 individuals with atopic asthma (mild/
moderate and severe) at the “Sotiria” Athens Chest Hospital, the Allergology
Department of the General Military Hospital of Athens, and the Lugano and
Milano University Hospitals. Asthma was defined according to the latest
guidelines from the Global Strategy for Asthma Management and Pre-
vention, Global Initiative for Asthma 2015 (ginasthma.org/2017-gina-report-
global-strategy-for-asthma-management-and-prevention). Severe asthma
was defined according to the latest American Thoracic Society (ATS)/Euro-
pean Respiratory Society (ERS) guidelines (38). Subjects did not receive
treatment with anti-IgE or anti–IL-5 monoclonal antibodies throughout the
study. Atopic and asthmatic individuals had a positive skin prick test result
(wheal size ≥ 3 mm) to LPS-free mixed grasses extract, and/or increased
allergen-specific IgE and blood samples were taken out of season. On
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Fig. 7. Therapeutic administration of human act-A–iTr1 cells reverses estab-
lished allergic airway disease. (A) AHR is depicted. Results are expressed as
means ± SEM. Data were analyzed as in Fig. 6A. (B) Representative photomi-
crographs and histological scores of H&E-stained lung sections. (Scale bars:
50 μm.) (C and D) CD4+ T cells were isolated from the peripheral blood of
asthmatics and stimulated with mitomycin-treated, CD3-depleted, mixed grasses
extract-loaded APCs, as indicated. 3[H]Thymidine incorporation and cytokine re-
lease in culture supernatants are depicted. Data are mean ± SEM of triplicate
wells (n = 10 donors). Statistical analysis was performed by a nonparametric
(Mann–Whitney) unpaired Student’s t test (*P < 0.05; **P < 0.01). Teff, T effector.
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entering the study, subjects were stable. Individuals with no clinical features of
infection for at least 4 wk before the start of the study and none throughout
the study period were included. Patients with autoimmune disorders, cancer,
and/or other respiratory diseases were excluded. The study was conducted
according to the principles described in the Declaration of Helsinki, and par-
ticipants signed a written informed consent form before inclusion in the study
approved by the ethics committee of “Sotiria” Athens Chest Hospital, Can-
tonal Ethical Committee of Cantone Ticino, ethics committee of “401 General
Military Hospital of Athens”, and Lugano and Milano University Hospitals.
Mice. Female (6–8 wk old) NOD-SCID mice were obtained from The Jackson
Laboratories, maintained at the Biomedical Research Foundation of the
Academy of Athens Animal Facility, and regularly checked for the absence of
serum Igs. Animal handling and procedures were in accordance with the US
NIH Statement of Compliance (Assurance) with Standards for Humane Care
and Use of Laboratory Animals (no. A5736-01) and with the European Union
Directive 86/609/European Economic Community(EEC) on protection of ani-
mals used for experimental purposes.
Isolation and Culture of Peripheral Blood T Cells. Peripheral blood mono-
nuclear cells (PBMCs) were obtained by Lymphoprep (Axis-Shield Diagnostics)
and/or Histopaque (Sigma–Aldrich) density-gradient centrifugation. Naive
CD4+ T cells were isolated using magnetic microbeads (CD4+CD25−CD45RO−;
Miltenyi Biotec) or by sorting with a FACS Aria cell sorter (BD Biosciences).
Cell viability staining was performed, and dying cells were excluded from
analyses. CD3-depleted PBMCs (Miltenyi Biotec) or CD14+ monocytes (Miltenyi
Biotec) were treated with mitomycin-C (Sigma–Aldrich) and used as APCs.
Similar results were obtained using either APC population, and results were
pooled for statistical analysis. Naive CD4+ T cells (2 × 104 cells) were stimu-
lated with autologous APCs (2 × 104 cells) loaded with LPS-free mixed grasses
extract [ALK-Abello, 1,000 standardized quality-units (SQ-U)/mL; kindly
provided by P. Wurtzen, ALK-Abello, Hørsholm, Denmark] in the presence of
PBS (Tconv cells) or recombinant activin-A (act-A-iTr1 cells, 50 ng/mL; R&D
Systems) for 7–9 d. In all in vitro stimulations, mixed grasses extract was
used. In certain experiments, naive CD4+ T cells were stimulated with plate-
bound anti-human CD3 (1 μg/mL, OKT3; BD Biosciences) and soluble anti-
human CD28 (1 μg/mL, CD28.2; BD Biosciences). Cells were cultured in RPMI
1640/GlutaMAX supplement medium with 10% FBS and 100 units/mL peni-
cillin and 100 μg/mL streptomycin (all from Gibco) in 96-well, U-bottomed
Nunc MicroWell Plates with Nunclon Delta Surface (Thermo Scientific). In
studies examining IL-10 production, cells were stimulated for an additional
24–48 h. Dose–response studies were performed to determine the optimal
doses of activin-A, allergen, and anti-CD3/CD28 antibodies. Human recombi-
nant IL-2 (20 international units/mL; R&D Systems); the Smad3 inhibitor SIS3
(10 nM; Sigma–Aldrich); CH-223191 (3 μM; Calbiochem); and neutralizing
antibodies against ALK4 (20 μg/mL; R&D Systems), IL-10R (20 μg/mL; R&D
Systems), and TGF-β (5 μg/mL; R&D Systems), or the respective Ig controls, were
added in cell cultures. To obtain CM, CD4+ T cells were isolated from activin-A–
or control-treated cultures, washed, and stimulated overnight with anti-CD3/
CD28 antibodies. CM was then added in cocultures of naive CD4+ T cells and
allergen-loaded APCs.
In other experiments, total CD4+ T cells (5 × 104 cells) obtained from atopic
and asthmatic individuals were isolated using magnetic microbeads (Miltenyi
Biotec) or the Dynal CD4 Positive Isolation Kit (Dynabeads; Invitrogen) and
stimulated with autologous APCs (2 × 104 cells) loaded with mixed grasses
extract for 4–5 d.
In experiments investigating T-cell hyporesponsiveness, CD4+ T cells were
isolated from primary induction cultures, labeled using a CellTrace CFSE
Proliferation Kit (Molecular Probes), and restimulated either with fresh
allergen-loaded APCs or with anti-CD3/CD28 antibodies for another 5–6 d.
In experiments investigating in vitro stability during prolonged culture,
CD4+ T cells were isolated from primary cultures as above and stimulated
every week with freshly isolated, allergen-loaded APCs for a period of 4 wk
and in the presence of IL-2.
For evaluation of Ag specificity, naive CD4+ T cells were cultured with
allergen-loaded, mitomycin-treated APCs in the presence of control (PBS) or
activin-A for two rounds of stimulation (7 d each); then, CD4+ T cells were
isolated and cultured with fresh APCs in the presence of tetanus toxoid
(5 μg/mL; Alexis Biochemicals) for another 6 d.
For in vitro human Tr1-cell generation, naive CD4+ T cells were stimulated
with plate-bound anti-CD3 and soluble anti-CD28 antibodies in the presence
of mitomycin-treated, CD3-depleted PBMCs and recombinant human (rh)
IL-10 (100 ng/mL; R&D Systems) and rhIFN-α2b (5 ng/mL; Merck). After 7 d,
T cells were restimulated under identical conditions for an additional 7 d. At
the end of the 14 d of culture, IL-10, CD49b, and LAG-3 expression was
analyzed by FACS. The fold expansion of T cells was calculated by dividing
the absolute number of cells after 14 d of in vitro culture by the absolute
number of cells at the start of the culture.
In Vitro Suppression Assays. Tconv or act-A–iTr1 cells (2 × 104 cells) were
stained with CFSE (Molecular Probes, Life Technologies) and cocultured with
Cell Trace Violet-labeled (Molecular Probes, Life Technologies) autologous
naive or Th2-effector/memory cells (at a 1:1 ratio) and allergen-loaded, au-
tologous, mitomycin-treated APCs for 4 d. A Transwell system (R&D Systems)
was used, wherein naive CD4+ T cells, APCs, and allergen were placed in the
bottom chambers and act-A–iTr1 or Tconv cells, APCs, and allergen were added in
the upper chambers. T-cell proliferation was evaluated by 3[H]thymidine in-
corporation or CFSE and Cell Trace Violet staining and analyzed by flow cytometry.
Neutralizing antibodies against activin-A (20 μg/mL; R&D Systems), IL-10R
(30 μg/mL; R&D Systems), ICOS ligand (ICOSL) (25 μg/mL; eBioscience), and
TGF-β (7.5 μg/mL; R&D Systems) were added in secondary suppressive cultures.
In other experiments, Tconv, act-A–iTr1, or IL-10–Tr1 cells were cocultured with
naive CFSE-labeled CD4+ T responders in the presence of anti-human CD3
(1 μg/mL) and soluble anti-human CD28 (1 μg/mL) for 5 d. The suppression of
cell proliferation was calculated by measuring the proliferation [3H]thymidine
incorporation or CellTrace proliferation dye dilution-based division index (39)
of T responders cultured across Tconv or act-A–iTr1 cells in comparison to
T responders alone, according to the formula:
100−
Proliferation  of  T-responder  cells  cultured  across  Tconv  or  act-A− iTr1
Proliferation  of  T-responder  cells  alone
× 100%.
Knockdown with shRNA. Naive CD4+ T cells (2 × 104 cells) were activated with
allergen-loaded APCs (2 × 104 cells) or anti-CD3/CD28 antibodies with or
without activin-A for 2.5 d. Cells were spun with lentivirus containing GFP-
expressing shRNA against human AHR, IRF4, or a scrambled RNA sequence
(Dharmacon) and 8 μg/mL polybrene (Sigma–Aldrich). Following 12 h of in-
cubation (37 °C), T cells were washed and differentiated for 3 d, as described
above. Transduced cells were selected by sorting of live GFP+ T cells, using a
FACS Aria cell sorter.
Cytokine Analysis. Cytokines were measured in culture supernatants and
mouse BAL using commercially available ELISA kits for human IL-10, IL-5, IL-4,
IL-13, IL-17, and IFN-γ (R&D Systems).
Flow Cytometry Analysis. Cells were stained with fluorescently labeled anti-
bodies to CD4, ICOS, PD-1, CTLA-4, GITR, CD25, CD69, CD127, LAG3, CD49b,
CCR3, CCR5, and CRTH2 (all from eBiosciences); CCR4 (BD Pharmingen); and
CCR6, CCR7, CXCR3, CD14, CD95, and CD45RA (all fromBiolegend). The staining
for CD49b and LAG3 was performed at 37 °C for 20 min (25). For intracellular
cytokine staining, T cells were restimulated with phorbol 12-myristate 13-
acetate (PMA)/ionomycin (Sigma–Aldrich) and Golgi-Stop (BD Biosciences), and
stained with antibodies against IL-4, IL-5, and IL-13 (all from eBiosciences); IL-17
(Beckman Coulter); and IFN-γ (Beckman Coulter) according to the manufac-
turers’ instructions. Foxp3 (eBiosciences) staining was performed according to
the manufacturer’s instructions. For IL-10 detection, T cells were restimulated
with anti-CD3/CD28 antibodies overnight. FACS acquisition was performed
with a Cytomics FC500 cytometer (Beckman Coulter) and an LSRFortessa
cytometer (BD Biosciences), and data were analyzed using FlowJo software.
Immunofluorescence Microscopy. T-cell cytospins (5 × 104 cells per slide) were
prepared in poly-L-lysine slides (Thermo Scientific), fixed in 4% (wt/vol) para-
formaldehyde (at 4 °C), and incubated in 10% sucrose. Slides were washed
twice and blocked in 10% donkey serum, and then diluted in 0.1% Triton-X
for 30 min. Slides were incubated overnight at 4 °C with primary biotinylated
antibodies against human AhR (Santa Cruz Biotechnology), c-Maf (Santa Cruz
Biotechnology), IRF4 (R&D Systems), or control IgG (R&D Systems). Slides were
then incubated with fluorescently labeled secondary antibodies (R&D Sys-
tems). Nuclear staining and mounting of the slides were carried out using
ProLong Gold Anti-Fade Reagent with DAPI (Life Technologies). Image ac-
quisition was performed by a confocal laser scanning microscope (Leica TCS
SP5), and images were acquired by differential interference contrast optics.
AhR+, c-Maf+, and IRF4+ T cells were counted in each cytospin by two in-
dependent observers and expressed as the percentage of total cells (40).
Reconstitution of NOD-SCID Mice. In the prevention protocol, NOD-SCID mice
were reconstituted on day 0 with 2 × 106 Tconv or act-A–iTr1 cells and 2 × 106
autologous APCs, and were immunized (i.p.) with Phleum pratense (5 μg per
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mouse in 0.2 mL of alum; kindly provided by P. Wurtzen) (28, 41). On day 1, mice
received autologous, BrdU-labeled, CD4+ T cells (106 cells). On days 9 and 10,
mice were challenged with aerosolized P. pratense; AHR was measured the
following day, and mice were killed. In other experiments, mice were adminis-
tered (i.p.) anti-human IL-10Rα (30 μg per mouse; Biolegend) or Ig control prior
to and 1 d following act-A–iTr1 cell (or Tconv cell) transfer. CD4+ T-responder
cells were incubated with anti–IL-10Rα antibody or Ig control before transfer. In
the therapeutic protocol, NOD-SCIDmice were reconstituted on day 0 with naive
CD4+ T cells (106 cells) and autologous APCs (106 cells), and were immunized with
P. pratense/alum. On day 8, mice received autologous Tconv or act-A–Tr1 cells
(2 × 106 cells). Mice were challenged and killed as described above.
AHR. AHR was measured by whole-body plethysmography (Buxco Research
Systems) to calculate enhanced pause (PenH) as described (18, 42).
BAL Analysis. BAL harvesting was performed as described and kept at −80 °C
until use (18, 42).
Lung Histology. Paraffin-embedded 4-μm lung sections were stained to evaluate
cell infiltration, and histological scores were obtained as described (18, 42).
Mouse Cell Culture, Oroliferation, and ex Vivo Suppression Assays. DLN cells
were isolated at the time of euthanasia and cultured at 106 cells per well with
2.5 μg/mL P. pratense. T-cell proliferation was measured by 3[H]thymidine
incorporation or BrdU staining, followed by flow cytometry.
Statistics. Data distribution was assessed with the D’Agostino–Pearson nor-
mality test. Analyses were performed using the Student’s t test and the
Mann–Whitney test as appropriate, using GraphPad Prism Version 5. AHR
was analyzed by two-way ANOVA for repeated measures, followed by the
Student’s t test. Any difference with a P value of 0.05 or less was considered
as statistically significant (*P < 0.05; **P < 0.01; ***P < 0.001). Additional
information regarding the quantitative real-time PCR, RNA-seq and bioinformatics
analysis, ChIP, in silico regulatory region analyses of selected genes, and
in silico structural study of AhR/IRF4/ARNT interactions is provided in SI
Materials and Methods.
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